ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer

European Journal of Cancer

Volumn 44, Issue 1, 2008, Pages 54-60

  Kim, Min Kyoung ^a   Cho, Kyung Ja ^b   Kwon, Gui Young ^b   Park, Seung Il ^b   Kim, Yong Hee ^b   Kim, Jong Hoon ^b   Song, Ho Young ^b   Shin, Ji Hoon ^b   Jung, Hwoon Yong ^b   Lee, Gin Hyug ^b   Choi, Kee Don ^b   Kim, Sung Bae ^a  

^a Asan Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Combined modality therapy; ERCC1; Oesophageal neoplasms

Indexed keywords

CAPECITABINE; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; ENDONUCLEASES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 37149046306     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.09.006     Document Type: Article

References (29)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
2. Urba S.G., Orringer M.B., Turrisi A., Iannettoni M., Forastiere A., and Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19 2 (2001) 305-313
3. Walsh T.N., Noonan N., Hollywood D., Kelly A., Keeling N., and Hennessy T.P. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335 7 (1996) 462-467
4. Lee J.L., Park S.I., Kim S.B., et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 15 6 (2004) 947-954
5. Burmeister B.H., Smithers B.M., Gebski V., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6 9 (2005) 659-668
6. Lee J.L., Kim S.B., Jung H.Y., et al. Efficacy of neoadjuvant chemoradiotherapy in resectable esophageal squamous cell carcinoma-a single institutional study. Acta Oncol 42 3 (2003) 207-217
7. Kim S.B., Park S.I., Kim J.H., et al. A phase II trial of preoperative one cycle of induction chemotherapy[capecitabine(CAP), CDDP] followed by concurrent chemoradiation(CRT) in patients with resectable esophageal cancer. J Clin Oncol 23 (2005) 4063 (abstract)
8. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J.J., and Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94 2 (1994) 703-708
9. Murray D., and Rosenberg E. The importance of the ERCC1/ERCC4[XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat Res 364 3 (1996) 217-226
10. Mu D., Hsu D.S., and Sancar A. Reaction mechanism of human DNA repair excision nuclease. J Biol Chem 271 14 (1996) 8285-8294
11. Sancar A. Mechanisms of DNA excision repair. Science 266 5193 (1994) 1954-1956
12. Santi D.V., McHenry C.S., and Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13 3 (1974) 471-481
13. Longley D.B., Harkin D.P., and Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3 5 (2003) 330-338
14. Kwon H.C., Roh M., Oh S., et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18 3 (2007) 504-509
15. Jakob C., Liersch T., Meyer W., et al. Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy. Am J Surg Pathol 29 10 (2005) 1304-1309
16. Lord R.V., Brabender J., Gandara D., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 7 (2002) 2286-2291
17. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 411 6835 (2001) 366-374
18. Warnecke-Eberz U., Metzger R., Miyazono F., et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 10 11 (2004) 3794-3799
19. Zhou W., Gurubhagavatula S., Liu G., et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10 15 (2004) 4939-4943
20. Carles J., Monzo M., Amat M., et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys 66 4 (2006) 1022-1030
21. Popat S., Matakidou A., and Houlston R.S. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22 3 (2004) 529-536
22. Kuniyasu T., Nakamura T., Tabuchi Y., and Kuroda Y. Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. Cancer 83 7 (1998) 1300-1306
23. Simon G.R., Sharma S., Cantor A., Smith P., and Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127 3 (2005) 978-983
24. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 10 (2006) 983-991
25. Zheng Z., Chen T., Li X., Haura E., Sharma A., and Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356 8 (2007) 800-808
26. Gazdar A.F. DNA repair and survival in lung cancer-the two faces of Janus. N Engl J Med 356 8 (2007) 771-773
27. Cobo M., Isla D., Massuti B., et al. Customizing cisplatin based on quantitative excision repair cross-completementing 1 mRNA expression: A phase III randomized trial in non-small cell lung cancer. J Clin Oncol 25 19 (2007) 2747-2754
28. Izzo J.G., Malhotra U., Wu T.T., et al. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24 5 (2006) 748-754
29. Ott K., Weber W.A., Lordick F., et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24 29 (2006) 4692-4698